Global Human Chorionic Gonadotropin (HCG) Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Chorionic Gonadotropin (HCG) Market Insights, Forecast to 2034
Human chorionic gonadotropin (HCG) is a female hormone produced by the placenta after implantation of the egg, which is why it can be detected in a few pregnancy tests. In addition, it can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology.
Market Analysis and InsightsGlobal Human Chorionic Gonadotropin (HCG) Market
Global Human Chorionic Gonadotropin (HCG) market is expected to reach to US$ 799.1 million in 2024, with a positive growth of %, compared with US$ 745.2 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Human Chorionic Gonadotropin (HCG) industry is evaluated to reach US$ 1173.2 million in 2029. The CAGR will be 6.6% during 2024 to 2029.
The growth of the human chorionic gonadotropin (HCG) market is attributed to the increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment. Hypogonadism, for example, is characterized by low serum testosterone concentration, which is followed by a number of clinical features such as erectile dysfunction (ED), poor morning erections, low libido, memory loss, physical decline in strength and health, difficulty concentrating, and depression.According to the study published by BMC Endocrine Disorders in July 2021, erectile dysfunction was found to be prevalent in 72.2% of people globally in 2021. Furthermore, according to the CDC update in March 2022, about 1 in 5 (22%) couples in which the woman is 30-39 have problems conceiving their first child, compared to about 1 in 8 (13%) couples in which the woman is younger than 30. Age-related fertility loss is mostly caused by deteriorating egg quality. Older women also have fewer remaining eggs and are more likely to have health issues that can affect fertility. Aging also increases a woman’s chances of miscarriage and of having a child with a genetic abnormality. Therefore, the high burden of infertility is also raising the demand for effective treatments such as human chorionic gonadotropin (HCG) hormones, which is fueling the market's growth.
Report Covers
This report presents an overview of global Human Chorionic Gonadotropin (HCG) market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Human Chorionic Gonadotropin (HCG) market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
EMD Serono, Inc
Ferring B.V
Merck & Co., Inc
Bristol Myers Squibb Company
Fresenius Kabi AG
Scripps Laboratories
Leebio
Kamiya Biomedical Company
Sanzyme
Cigna
LUPIN
Sun Pharmaceutical Industries Ltd
Serum Institute of India Pvt. Ltd
VHB Medi Sciences Limited
Zydus Lifesciences Ltd
Corona Remedies Pvt. Ltd.
Segment by Type
Natural Source Extraction
Recombinant DNA Technology
Female Infertility Treatment
Oligospermic Treatment
Cryptorchidism Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Human Chorionic Gonadotropin (HCG) introduction, etc. Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Human Chorionic Gonadotropin (HCG)
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Human Chorionic Gonadotropin (HCG) Market
Global Human Chorionic Gonadotropin (HCG) market is expected to reach to US$ 799.1 million in 2024, with a positive growth of %, compared with US$ 745.2 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Human Chorionic Gonadotropin (HCG) industry is evaluated to reach US$ 1173.2 million in 2029. The CAGR will be 6.6% during 2024 to 2029.
The growth of the human chorionic gonadotropin (HCG) market is attributed to the increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment. Hypogonadism, for example, is characterized by low serum testosterone concentration, which is followed by a number of clinical features such as erectile dysfunction (ED), poor morning erections, low libido, memory loss, physical decline in strength and health, difficulty concentrating, and depression.According to the study published by BMC Endocrine Disorders in July 2021, erectile dysfunction was found to be prevalent in 72.2% of people globally in 2021. Furthermore, according to the CDC update in March 2022, about 1 in 5 (22%) couples in which the woman is 30-39 have problems conceiving their first child, compared to about 1 in 8 (13%) couples in which the woman is younger than 30. Age-related fertility loss is mostly caused by deteriorating egg quality. Older women also have fewer remaining eggs and are more likely to have health issues that can affect fertility. Aging also increases a woman’s chances of miscarriage and of having a child with a genetic abnormality. Therefore, the high burden of infertility is also raising the demand for effective treatments such as human chorionic gonadotropin (HCG) hormones, which is fueling the market's growth.
Report Covers
This report presents an overview of global Human Chorionic Gonadotropin (HCG) market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Human Chorionic Gonadotropin (HCG) market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
EMD Serono, Inc
Ferring B.V
Merck & Co., Inc
Bristol Myers Squibb Company
Fresenius Kabi AG
Scripps Laboratories
Leebio
Kamiya Biomedical Company
Sanzyme
Cigna
LUPIN
Sun Pharmaceutical Industries Ltd
Serum Institute of India Pvt. Ltd
VHB Medi Sciences Limited
Zydus Lifesciences Ltd
Corona Remedies Pvt. Ltd.
Segment by Type
Natural Source Extraction
Recombinant DNA Technology
Segment by Application
Female Infertility Treatment
Oligospermic Treatment
Cryptorchidism Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Human Chorionic Gonadotropin (HCG) introduction, etc. Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Human Chorionic Gonadotropin (HCG)
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices